biuro@scopefluidics.com +48 22 376 21 14

About
Team
Our offer
Knowledge base
News
Investor relations
Career
Contact

biuro@scopefluidics.com +48 22 376 21 14

About
Team
Our offer
Knowledge base
News
Investor relations
Career
Contact

biuro@scopefluidics.com +48 22 376 21 14

RAPORT ESPI 20/2021 | 02-06-2021 | Rozpoczęcie certyfikacyjnych testów klinicznych na panel SARS-CoV-2

Previous PostRAPORT ESPI 19/2021 | 01-06-2021 | Otrzymanie przez Bacteromic certyfikatu ISO 13485:2016Next PostRAPORT EBI 6/2021 | 02-06-2021 | Zwołanie Zwyczajnego Walnego Zgromadzenia Scope Fluidics S.A. na 30 czerwca 2021 r.

0Shares

Related Posts

Scope Fluidics Named “Stock Exchange Company of the Year 2024″ by Puls Biznesu

Scope Fluidics Reports Positive Results from Software Development for Rapid Detection

EAP Results Confirm Readiness for BACTEROMIC System Market Deployment

CONTACT US

Tel. +48 22 376 21 14
Email: biuro@scopefluidics.com

Address

Ogrodowa 58
9th floor
00-876 Warsaw

KRS: 0000668408

NIP: 527-264-59-89

REGON: 142-754-170

LEI: 259400EUNFX4E2BEHU15

Company registered in the District Court for the Capital City of Warsaw in Warsaw, XII Commercial Division of the National Court Register.

Share capital: PLN 272 593,00 fully paid up

Bank Account Number: 03 2490 0005 0000 4520 3046 2136

Terms of use

Cookies Policy

Whistleblower Protection

Scope Fluidics 2021 ® All rights reserved